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Abstract
Fetal lower urinary tract obstruction (LUTO) is a serious condition, which commonly results in marked perinatal
morbidity and mortality. The characteristic prenatal presentation of LUTO includes an enlarged bladder with
bilateral obstructive uropathy. While mild forms of the disease result in minimal clinical sequelae, the more severe
forms commonly lead to oligohydramnios, dysplastic changes in the fetal kidneys, and ultimately result in
secondary pulmonary hypoplasia. The aim of this review is to provide practitioners with a practical and concise
overview of the presentation, evaluation, and treatment of LUTO.
Introduction
Lower urinary tract obstruction (LUTO) in the fetus can
result in increased perinatal morbidity by causing abnor-
mal development of the urinary tract along with under-
development of the lungs [1, 2]. The characteristic pre-
natal presentation of LUTO includes an enlarged bladder
(Fig. 1) with bilateral hydroureteronephrosis [1, 2]. While
mild forms of the disease, as seen in functional defects,
may lead to minimal clinical sequelae, the more severe
forms commonly lead to oligohydramnios, a distended
urinary tract, renal dysplasia (Fig. 2), as well as pulmonary
hypoplasia [1, 2]. The aim of this review is to provide the
practitioner with a practical and concise overview of the
presentation, evaluation, and treatment of LUTO.
Review
Incidence
The incidence of LUTO has been reported to be between
1 in 5,000 to 1 in 25,000 pregnancies, which may be an
underestimation given that there is no accounting for
cases of elective termination, intrauterine fetal demise
(IUFD), or postnatal diagnosis [3, 4]. The two most com-
mon causes of LUTO include posterior urethral valves
(PUVs), and urethral atresia [5]. In general, obstruction at
the bladder outlet in males is caused by PUVs, whereas in
females it is secondary to urethral atresia [4].
Presentation
The sonographic features of LUTO include marked dis-
tention of the bladder, often with a thickened wall
(greater than 2 mm) [4]. A “keyhole” sign may be seen
in cases of PUV, which reflects dilation of the posterior
urethra, proximal to the level of the obstruction; how-
ever the “keyhole” sign (Fig. 1) is not a specific ultra-
sound sign of PUV and may also be present in different
causes of LUTO [6]. While ureterectasis (dilation of the
ureter) and caliectasis (dilation of renal calices) are com-
mon findings in cases of LUTO, it must be noted they
are only present in 40–50 % of cases and their absence
should not rule out the diagnosis of bladder obstruction
[6]. The vesicourethral reflux from the increased intrave-
sical pressure may lead to pan dilation of the urinary
tract, and the increased pressure in turn may result in
dysplastic renal changes (Fig. 2) [5]. Accordingly, the
presence of subcortical cysts, small and hyperechoic
kidneys, as well as absence of caliectasis should raise
suspicion for end-stage obstructive uropathy [7, 8].
Long-standing oligohydramnios resulting from LUTO
may lead to fetal anatomical deformities including club-
feet and Potter facies [7, 8].
Differential diagnosis
The differential diagnosis of LUTO is highly dependent on
the fetal gender [5, 8, 9]. As mentioned earlier, in the male
fetus the most likely diagnosis is PUVs; however, other rare
causes such as a prolapsing uretereocele from a duplicated
collecting system must be kept in mind [5, 8, 9].
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In the female fetus, urethral atresia is the most common
cause; however, persistent cloaca, caudal regression, and
megacystis-microcolon-intestinal hypoperistalsis syndrome
must be ruled out. [5, 8, 9]. A persistent cloaca generally
presents with an enlarged bladder prior to 16 weeks gesta-
tion, and will often accompany presence of debris within
the cloaca, and intraluminal calcifications within bowel
loops (due to intestinal communication) [2, 10–13]. Caudal
regression generally presents with normal amniotic fluid
volume, vertebral and lower extremity defects, and bladder
extrophy. Megacystis-microcolon-intestinal hypoperistalsis
syndrome again presents with normal to high amniotic
fluid volume, dilated bladder with a thin wall, as well as
dilated loops of bowel [13].
Evaluation
Initial evaluation of the fetus with suspected LUTO
should include a comprehensive anatomic survey and
echocardiogram to rule out any co-existing abnormal-
ities, gender determination, amniotic fluid volume as-
sessment, as well as diagnostic genetic evaluation given
that over 10 % of LUTO cases are associated with Triso-
mies 13, 18, or 21 [2, 5, 12, 13]. Given the latter point, it
is highly recommended that the parents meet with a
genetic counselor as part of the diagnostic and treatment
process.
In non-isolated cases of LUTO, strong consideration
should be given to an underlying genetic process, and
invasive prenatal diagnosis initiated as the presence of a
Fig. 1 Ultrasound image of fetal bladder obstruction with the characteristic “keyhole” sign (B: Bladder, u: urethra)
Fig. 2 Ultrasound image of hyperechoic and small for gestational age fetal kidneys, secondary to fetal lower urinary tract obstruction
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genetic abnormality may preclude candidacy for fetal
intervention [14, 15].
In isolated cases of LUTO with normal amniotic fluid
volume, an amniocentesis should be offered to rule out
an underlying genetic disorder [2, 13]. Otherwise, evalu-
ation should consist of serial assessments of the fetal
anatomy (every 1–2 weeks) to rule out late developing
abnormalities (e.g. oligohydramnios, renal dysplasia)
[16]. As discussed later, normal amniotic fluid volume
generally denotes a milder form of disease, and does not
require fetal intervention [2, 16].
In isolated LUTO cases with oligohydramnios, a thor-
ough discussion should be held with the parents before
proceeding with invasive evaluations of the fetus, to ascer-
tain the parental wishes for intervention [9, 12]. Should the
parents elect to terminate the pregnancy, genetic testing
should be highly recommended as in some cases (e.g.
Megacystis-microcolon-intestinal hypoperistalsis syndrome)
the recurrence risk might be as high as 25 % (due to auto-
somal recessive inheritance) [5, 17–20]. Should the parents
elect intervention, invasive testing (as outlined below)
should be undertaken to assess renal function, and genetic
make up of the fetus.
Evaluation of the fetus should begin with two consecu-
tive diagnostic vesicocenteses (bladder taps) [21–24].
Under ultrasound (US) guidance, the bladder should be
visualized in its largest dimensions, and a point of entry
(preferably avoiding the placenta) should be identified,
where the needle tip is ideally placed in the lower aspect
of the bladder [23, 24]. Care should be taken (e.g. use of
color Doppler) to avoid injury to intra-abdominal struc-
tures such as the umbilical arteries. Using a 22 gauge
spinal needle, the bladder should be drained as much as
safely and technically possible. This first specimen should
be sent for genetic evaluation including a complete gen-
omic hybridization microarray. A recent report demon-
strated a 100 % result rate from fetal urine specimens,
obviating the need for an amniocentesis or placental
biopsy [15]. Excess urine from the first drainage may be
sent for electrolyte evaluation as well, provided that there
is enough volume to complete the genetic evaluation as
well. It must be cautioned that unfavorable electrolyte
analysis should not be viewed as an exclusion criterion for
intervention, and electrolyte analysis from a second drain-
age should be sent, as stagnant urine may not accurately
reflect the correct renal function. The second vesicocent-
esis should be performed 24–48 h later in similar fashion,
and the urine sample sent for sodium (Na), chloride (Cl),
osmolarity (Osm), calcium (Ca), and beta-2 microglobulin
(β2) [23, 24]. The prognostic criteria suggested by Glick &
colleagues, [25–27] as outlined in Table 1, along with the
sonograophic appearance of the kidneys should be used in
assessing candidacy for intervention. For a fetus to be cat-
egorized as having “good” prognostic indicators, the values
in Table 1 (especially Na, Cl, Osm, Ca) should be within
the favorable range, and the sonographic assessment of
the fetal kidneys should not demonstrate absence of cor-
tical cysts or hyperechogenicity.
Before proceeding with the treatment options for
LUTO, it is prudent to mention one major limitation of
the above prognostic indicators in that the values are
not adjusted for gestational age (fetal urine becomes
more hypotonic until reaching its nadir at 20–21 weeks),
nor are they reflective of postnatal renal function, there-
fore the parents should be cautioned regarding the pos-
sibility of poor renal function at time of birth despite
intervention [23].
Treatment
As mentioned earlier, elective termination of the preg-
nancy should be discussed with couples facing a child
with LUTO. Those that elect to continue the pregnancy
should meet with a Pediatric Nephrologist and Urologist
to review the possible postnatal courses including short
and long-term outcomes (e.g. dialysis, transplantation)
so that realistic expectations are set.
For fetuses with a favorable prognostic indicators (Table 1)
and oligohydramnios, treatment is predominantly aimed at
restoration of amniotic fluid volume for prevention of pul-
monary hypoplasia, and urinary decompression for attenu-
ation of on-going renal damage [20, 24]. Treatment options
for this subset of fetuses includes vesicoamniotic shunting
(most commonly used), valve ablation via cystoscopy, and
vesicostomy.
Vesicoamniotic shunting is a percutaneous procedure
performed under ultrasound guidance, using local
anesthesia for maternal pain relief [7]. Prior to placement
of the shunt, an amnioinfusion (e.g. warm sterile saline
infused with Nafcillin) is routinely required to allow space
for deployment of the proximal end of the catheter.
Fentanyl (15 μgLKg) and pancuronium (0.5–2 mg/Kg) in-
jection into the umbilical vein or into the fetal arm muscle
may be used for fetal anesthesia. A double pig tailed cath-
eter (Rodeck/Rocket or Harrison shunts) is then placed
with the distal end in the fetal bladder, and proximal end
within the amniotic cavity (Fig. 3) [2]. It must be noted
that due to the small caliber and long length of the shunts,
complete decompression of the bladder or the urinary
tract may not be seen in all cases, especially those with a
Table 1 Prognostic criteria using fetal urine [25]
Urinary component Favorable
Sodium (Na) Less than 100 mEq per liter
Chloride (Cl) Less than 90 mEq per liter
Osmolarity (Osm) Less than 210 mEq per liter
Calcium (Ca) Less than 2 mmol per liter
Beta-2 microglobulin Less than 2 mg per liter
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high-grade obstruction. The outcomes associated with
vesicoamniotic shunting are not clear [28]. Data to date
have not proven reliable due to heterogenous patient pop-
ulations. Furthermore, the most recent randomized trial
aimed at examining the utility of vesicoamniotic shunting
(PLUTO Trial) ended prematurely without answering this
important question due to poor recruitment, although
anecdotal evidence appears to point to improved out-
comes with this intervention [5, 28].
Fetal cystoscopy, which is technically more difficult
than vesicoamniotic shunt placement, is an emerging
treatment option for LUTO [29–31]. This option holds
several advantages over shunting in that it allows for dir-
ect visualization of the obstruction to ascertain specific
diagnosis (Fig. 4), and does not require an amnioinfusion
[2]. Given the need for minimal maternal movement, as
well as the longer procedure duration, consideration
should be given for maternal regional (epidural or
spinal) anesthesia, rather than local analgesia. Similar to
vesicoamniotic shunting, fetal anesthesia may be accom-
plished by injecting fenatnyl (15 μgLKg) and pancuro-
nium (0.5–2 mg/Kg) into the umbilical vein or into the
fetal arm muscle. Using a larger trocar (2.2 mm) than
used for vesicoamniotic shunting (1.6 mm), a 1.0 mm fe-
toscope in a curved sheath and at least a 70° field of
view is used for cystoscopy [2, 5, 17, 32, 33]. After con-
firming that the trochar is inside the fetal bladder, the fe-
toscope is introduced into the sheath, and advanced
toward the bladder neck and the dilated posterior ur-
ethra. If a membrane-like obstruction of the urethral
lumen is seen, the diagnosis of PUV is confirmed and
the valves can be treated using hydroablation, guide-wire
or laser fulguration [2, 5, 17, 32, 33]. However, if a non-
membrane-like structure is found, even with the fluid in-
jection, the UA is diagnosed and no attempt to perforate
this structure is performed, and a vesicoamniotic shunt
is placed [2, 5, 17, 32, 33]. The main complication of
fetal cystoscopic laser ablation of PUV is urological fis-
tula, which seems to be associated with less operator ex-
perience, elevated laser power/energy and less curved
instruments [34]. Therefore, percutaneous fetal cystos-
copy is useful for diagnostic as well as therapeutic pur-
poses in LUTO, however it is necessary to have
adequate experience and instruments to perform this
challenging procedure. Lastly, given that this procedure
remains experimental, it should be performed under in-
stitutional review board approval.
Fetal vesicostomy, via open fetal surgery, is yet another
treatment option for LUTO [35, 36]. However, despite
its promising neonatal results, the associated maternal
and perinatal morbidity, along with the paucity of large
scale data preclude it’s widespread use for the treatment
of LUTO at this time. In addition, this technique does
not improve the bladder function [35]. Despite the
promising results for each of the above interventions,
there remains a paucity of high quality data supporting
the use of fetal intervention in cases of LUTO with a
favorable prognostic profile and oligohydramnios.
With respect to outcomes for the abovementioned inter-
vention, a recent review by Morris and Kilby provided a
useful overview [7]. Vesicoamniotic shunting improved
perinatal survival when compared with no treatment (odds
ratio (OR) 3.86; 95 % confidence intervals (CI) 2.00–7.45),
albeit at the expense of residual risk of poor long-term
postnatal renal function (OR 0.67, 95 % CI 0.22–2.00).
Similarly, cystoscopy appears to improve perinatal survival
by an OR of 20.51 (95 % CI 3.87–106.89); however, when
compared to shunting, there appears to be no significant
Fig. 3 Ultrasound image of a vesicoamniotic shunt with the two
catheter ends (S) in the fetal bladder (B) and amniotic cavity (A)
Fig. 4 Fetal cystoscopy image within the bladder (B) demonstrating
the point of obstruction at the urethra (U)
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improvement in perinatal survival OR 1.49 (0.13–16.97).
Appropriately, they concluded that while prenatal interven-
tion appears to improve perinatal survival, there might be a
trend towards increased childhood morbidity (associated
with chronically poor renal function) in the survivors, a
point which should be made clear to the parents at the time
of diagnosis [7].
Expectant management is yet another option for cou-
ples facing this serious problem in their child. In cases
of LUTO with preserved normal amniotic fluid levels,
favorable pulmonary function should be expected. The
parents should meet with pediatric subspecialists to pre-
pare for the postnatal course, which may include surgery
and dialysis. In cases of LUTO with oligohydramnios,
palliative care should be offered. In the event the parents
decline palliative care, consultation with pediatric sub-
specialists, especially Neonatology should be undertaken
to prepare the parents for expected complications espe-
cially pulmonary hypoplasia. Furthermore, discussions
between the obstetric team and the parents should be
held to review parental wishes for intervention in the
event of non-reassuring fetal status considering the poor
prognosis.
Lastly, consideration for intervention should be given
for those fetuses with a poor prognostic profile, or end-
stage fetal renal disease, which are not candidates for the
above interventions [2]. While termination of the preg-
nancy or palliative care is the uniformly accepted recom-
mendation for these cases, they may not be an option
for some parents due to personal or religious beliefs. In
such instances, under an experimental and case-by-case
basis, some groups (including the author) have offered
serial amnioinfusions(Fig. 5) for pulmonary palliation
[37, 38]. The couple is asked to meet with Neonatology,
Pediatric Urology, and Pediatric Nephrology to thoroughly
review the expected outcomes (including morbidity and
mortality) of a neonate with end-stage renal disease re-
quiring dialysis and transplantation. If still interested, ser-
ial amnioinfusions are performed for oligohydramnios
until 28–30 weeks, and delivery for fetal distress reserved
until an estimated fetal weight of 2–2.5 kg to allow for
peritoneal dialysis cathether placement candidacy. It must
be noted that this intervention is experimental, and large-
scale studies are needed to assess its utility and safety.
Conclusions
LUTO can lead to marked morbidity and mortality in
the fetus; therefore it is prudent for obstetric providers
to understand it’s general presentation, and management
principles. While several treatment modalities exist, in-
cluding vesicoamniotic shunting and fetal cystoscopy,
large scale studies are needed to validate their efficacy in
preventing pulmonary hypoplasia, and preserving renal
function.
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